Why Did Thyrocare Technologies Shares Crash 9% Today? Here’s What You Need to Know
This Healthcare Stock, engaged in providing diagnostic and preventive healthcare services, including pathology testing, clinical chemistry, thyroid testing, specialised diagnostics, and preventive health check-ups through its laboratory network, fell 8.73 percent after the company reported weak September quarterly results with a 70.35 percent QoQ decrease in net profit.
With a market capitalization of Rs. 7,592.98 crores, the share of Thyrocare Technologies Limited has reached an intraday low of Rs. 470.20 per equity share, down nearly 8.73 percent from its previous day’s closing price of Rs. 515.20. Since then, the stock has retreated and is currently trading at Rs. 477.05 per equity share.
Also Read: Sensex & Nifty 50 | Stock Market Live Updates Today: Markets Open Mixed: Sensex Edges Up, Nifty Flat; IT Gains 1.11%
Q2 FY27 Result Walkthrough
Thyrocare Technologies Limited reported a sharp decline in profitability in Q2 FY27, with consolidated net profit falling 68.17 percent year-on-year to Rs. 15.22 crore from Rs. 47.81 crore in Q2 FY26. On a sequential basis, net profit declined 70.35 percent from Rs. 51.33 crore in Q1 FY27.
Thyrocare’s profitability was impacted by an exceptional impairment loss of Rs. 44.98 crore on its investment in NHL, following a reassessment based on the latest valuation report. Excluding this one-time charge, the company’s profit before tax would have been approximately Rs. 78.63 crore.
The company’s consolidated revenue from operations increased by 25.07 percent YOY, from Rs. 216.53 crore in Q2 FY26 to Rs. 270.81 crore in Q2 FY27, and grew by 12.83 percent QoQ from Rs. 240.02 crore in Q1 FY27.
The basic earnings per share decreased by 68.21 percent and stood at Rs. 0.96 as against Rs. 3.02 recorded in the same quarter in the previous year, FY2026.
Geographical Presence
Thyrocare Technologies Limited has established a strong pan-India presence with a network of 49 laboratories, allowing the company to serve customers across different parts of the country. Its network includes 26 Regional Processing Labs (RPL), 8 Hybrid Labs, 6 Specialised Processing Labs (SPL), 4 Acquired Labs, 3 Central Processing Labs (CPL) and 2 Zonal Processing Labs (ZPL). The company also operates one international laboratory in Tanzania.
Region-wise, the company has the highest number of laboratories in the North with 17 labs, followed by the South with 12 labs, the West with 10 labs, and the East with 9 labs. This wide network helps improve its geographical reach and diagnostic service availability.
Segment Revenue Mix
Thyrocare Technologies Limited generated total revenue of Rs. 270.81 crore in Q2 FY27. Diagnostic Testing Services remained the largest contributor, accounting for Rs. 256.74 crore or 94.8 percent of total revenue. Imaging Services contributed Rs. 13.55 crore, representing 5.0 percent, while other services added Rs. 0.52 crore or 0.2 percent.
The company's region-wise pathology revenue mix shows that the West region contributes the highest share at 29 percent, followed by the South at 26 percent. The North region accounts for 24 percent of total pathology revenue, while the East contributes 21 percent.
Future Outlook
Thyrocare Technologies Limited is focusing on strengthening its business through franchise expansion, strategic partnerships, and specialised diagnostic services. The company plans to expand its franchise network by providing better training and support. It is also building partnerships with healthcare companies, corporates, and insurance providers to improve its reach and make diagnostic services more accessible.
Also Read: Alivus Life Sciences Jumps 7% as EBITDA Margin Hits Record 41.8%: What's Driving the Profit Surge?
Additionally, the company is expanding its specialised testing services in advanced pathology, genomics and biomarker-based diagnostics to tap high-growth opportunities. It is also increasing engagement with doctors and clinicians to build trust, improve awareness, and encourage the use of its diagnostic services.
Company Overview
Thyrocare Technologies Limited is an Indian healthcare company headquartered in Navi Mumbai, Maharashtra, established in 1996. The company is engaged in providing diagnostic and preventive healthcare services through a network of fully automated, technology-enabled laboratories. Its services include pathology testing, clinical chemistry, thyroid testing, metabolic and chronic disease screening, preventive health check-ups, and specialised diagnostics.
Annual Performance of FY26
Thyrocare Technologies Limited’s revenue has increased from Rs. 687 crore in FY25 to Rs. 829 crore in FY26, which has grown by 20.67 percent. The net profit has also grown by 79.12 percent from Rs. 91 crore in FY25 to Rs. 163 crore in FY26.
Also Read: CARE Ratings Q2: Net Profit Rises 26.6% to ₹71.8 Crore, Revenue Grows 20.6% YoY
Thyrocare Technologies Limited’s revenue and net profit have grown at a CAGR of 11 percent and 8 percent, respectively, over the last five years. In terms of return ratios, the company's ROCE and ROE stand at 35.4 percent and 28.4 percent, respectively. Thyrocare Technologies Limited’s debt-to-equity ratio is 0.10x.